After Vivus (Nasdaq: VVUS ) posted earnings last week, the company's share price took a big hit due to unimpressive sales of obesity drug Qsymia. With competitor Arena Pharmaceuticals (Nasdaq: ARNA ) and its partner Eisai poised to enter this space with its own drug Belviq in the first quarter of next year, VIVUS might be starting to feel pressure to boost sales.
While investors need to continue watching Qsymia sales quarter to quarter, VIVUS looks determined to expand the possible uses for its flagship drug. In this video, Health Care Analyst Max Macaluso discusses a new clinical study that suggests Qsymia might widen its indication in the future.
The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies are looking to change everything. Newly-approved drugs, including VIVUS' flagship drug, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense, but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health-care writer on the job, so make sure to secure a copy today by clicking here now.